

Please type a plus sign (+) inside this box → 

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1644

# TRANSMITTAL FORM

*(to be used for all correspondence after initial filing)*

Total Number of Pages in This Submission

Application Number	09/992,524
Filing Date	November 13, 2001
First Named Inventor	Vasquez, Maximiliano
Group Art Unit	1644
Examiner Name	G. Ewoldt
Total Number of Pages in This Submission	4
Attorney Docket Number	011823-008120US

RECEIVED


FEB 13 2003

TECH CENTER 1600/2900

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i>	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i>
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Third Preliminary Amendment
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.



## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP	Reg. No. 37,505
Signature		
Date	February 6, 2003	

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

February 6, 2003

Typed or printed name  Paula Faulk HurleySignature 

Date

February 6, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 328215 v1



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 011823-008120US

Assistant Commissioner for Patents  
Washington, D.C. 20231

On January 14, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Paula Faulk Hurley Paula Faulk Hurley

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Vasquez et al.

Application No.: 09/992,524

Filed: November 13, 2001

For: HUMANIZED ANTIBODIES TO  
GAMMA-INTERFERON

Examiner: G. Ewoldt

Art Unit: 1644

**THIRD PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

**IN THE SPECIFICATION:**

Please replace the paragraph beginning on page 5, line 5 with the following rewritten paragraph:

Fig. 3: Comparison of the mature heavy chain variable region amino acid sequence of humanized immunoglobulin HuZAF, humanized immunoglobulin haf25, and humanized immunoglobulin HuXAF.

#5/C  
JRW  
3/15/03  
**RECEIVED**  
TECH CENTER 1600/2800

FEB 13 2003